Mankind Pharma Limited — Others, 14-05-2025: Monitoring Agency Report

Mankind Pharma has announced a board meeting to review the financial results for the quarter and half-year. CARE Ratings, the monitoring agency for its Rs. 3000 Cr QIP, confirmed proper utilization of proceeds, primarily used to repay Commercial Paper Series I (Rs. 2900 Cr). Rs. 55 Cr was used for general corporate purposes, including debt repayment. Issue expenses of Rs. 42.54 Cr were mostly incurred, with Rs. 2.43 Cr pending. The agency reported full compliance with the issue’s objectives and no delays or adverse impacts on fund usage.